Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus.
使用胰高血糖素樣肽-1受體激動劑不會增加2型糖尿病患者罹患癌症的風險。
Diabetes Metab J 2024-10-23
Glucagon-Like Peptide 1-Based Therapies and Risk of Pancreatic Cancer in Patients With Diabetes and Obesity.
糖尿病和肥胖患者中胰臟癌風險的胰高血糖素樣肽1基礎治療。
Pancreas 2023-05-01
Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study.
糖尿病患者使用 GLP-1 受體激動劑和 DPP-4 抑制劑與甲狀腺癌風險相關性：一項基於人口的世代研究。
Diabetes Obes Metab 2023-12-16
Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study.
糖尿病患者中胰高血糖素樣肽-1受體激動劑與皮膚癌風險：人口基礎的世代研究。
Diabet Med 2024-03-15
Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes.
二型糖尿病患者中胰臟癌風險與葡萄糖樣肽-1受體激動劑的關聯。
JAMA Netw Open 2024-01-08
The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study.
糖尿病患者使用 GLP-1 受體激動劑不會增加胰臟癌風險：美國基礎的世代研究。
Cancers (Basel) 2024-05-13
Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes.
糖尿病患者中胰高血糖素樣肽-1受體激動劑與13種與肥胖相關的癌症。
JAMA Netw Open 2024-07-05
Risk of Esophageal and Gastric Cancer in Patients with Type 2 Diabetes Receiving Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A National Analysis.
接受胰高血糖素樣肽-1 受體激動劑 (GLP-1 RAs) 的第二型糖尿病患者食道和胃癌風險：一項全國性分析。
Cancers (Basel) 2024-09-28
GLP-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data.
GLP-1 受體激動劑與胰臟癌風險：使用真實世界數據的目標試驗模擬。
J Natl Cancer Inst 2024-10-17
The potential adverse effects of hypodermic glucagon-like peptide -1 receptor agonist on patients with type 2 diabetes: A population-based study.
對2型糖尿病患者使用皮下注射的胰高血糖素樣肽-1受體激動劑的潛在不良影響：一項基於人群的研究。
J Diabetes 2024-10-22